TG Therapeutics TGTX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $442.21M+459% | $79.15M+6.8% | $74.08M-42.6% | $129.13M-2.3% | $132.14M-26.5% | ||
| $1.35M+0.7% | $1.34M+1.0% | $1.33M+1.0% | $1.32M+1.1% | $1.3M+0.3% | ||
| $1.19B+20.3% | $992.65M+21.6% | $816.21M+22.5% | $666.55M+28.5% | $518.64M+31.8% | ||
| $344.19M-27.6% | $475.6M+3.4% | $459.91M+15.7% | $397.63M+22.9% | $323.67M+32.9% | ||
| $51.46M-10.6% | $57.58M+3.1% | $55.85M+120% | $25.37M+24.4% | $20.39M+29.7% | ||
| $1.09B+72.3% | $630.76M+5.2% | $599.77M-9.7% | $663.96M+3.0% | $644.51M+13.8% | ||
| $6.48M+3.2% | $6.28M-3.4% | $6.5M-3.2% | $6.72M-3.0% | $6.93M-3.1% | ||
| —— | —— | —— | —— | —— | ||
| $2.02M-1.4% | $2.04M0.0% | $2.05M+0.9% | $2.03M-0.7% | $2.04M— | ||
| $61.54M+4.1% | $59.14M+21.3% | $48.76M+70.5% | $28.59M+1,399% | $1.91M+136% | ||
| $72.22M+15.0% | $62.82M+9.3% | $57.5M-53.2% | $122.74M-14.8% | $144.1M+9.9% | ||
| $1.53B+43.8% | $1.06B+3.7% | $1.03B+45.9% | $702.61M+7.0% | $656.69M+13.7% | ||
| $148.85M+38.5% | $107.51M-4.3% | $112.34M-16.2% | $134.02M+0.1% | $133.93M+130% | ||
| $596K-71.9% | $2.12M+6.6% | $1.99M-11.7% | $2.26M-23.4% | $2.95M-36.3% | ||
| $18.66M-14.6% | $21.85M+45.5% | $15.01M+41.5% | $10.61M+107% | $5.14M-66.2% | ||
| $6.86M-22.1% | $8.81M+5.5% | $8.35M+401% | $1.67M-74.7% | $6.6M-45.4% | ||
| $1.82M+74.5% | $1.04M-2.2% | $1.07M-2.1% | $1.09M-2.2% | $1.12M-3.5% | ||
| $187.11M+21.7% | $153.76M-1.9% | $156.81M-8.8% | $171.89M+7.3% | $160.21M+76.7% | ||
| $745.14M+203% | $245.65M+0.1% | $245.34M+0.1% | $245.04M+0.1% | $244.73M+0.1% | ||
| $6.6M-6.1% | $7.02M-3.9% | $7.31M-3.7% | $7.59M-3.5% | $7.86M-3.4% | ||
| $8.42M+4.4% | $8.07M-3.7% | $8.38M-3.5% | $8.68M-3.3% | $8.98M-3.4% | ||
| $945.71M+128% | $415.23M-0.6% | $417.81M-2.0% | $426.18M+1.6% | $419.4M+18.0% | ||
| $160K+0.6% | $159K0.0% | $159K0.0% | $159K0.0% | $159K+1.9% | ||
| $1.85B+0.8% | $1.83B+1.0% | $1.81B+1.0% | $1.79B+1.0% | $1.78B+0.9% | ||
| -$1.06B+1.8% | -$1.08B+2.1% | -$1.11B+26.1% | -$1.5B+1.8% | -$1.52B+0.3% | ||
| $200.23M+99.8% | $100.23M0.0% | $100.23M+356% | $21.99M+45.5% | $15.12M+68.1% | ||
| $583.13M-10.0% | $648.02M+6.7% | $607.22M+120% | $276.43M+16.5% | $237.29M+6.7% | ||
| $1.53B+43.8% | $1.06B+3.7% | $1.03B+45.9% | $702.61M+7.0% | $656.69M+13.7% | ||
| $51.46M-10.6% | $57.58M+3.1% | $55.85M+120% | $25.37M+24.4% | $20.39M+29.7% | ||
| $2.02M-1.4% | $2.04M0.0% | $2.05M+0.9% | $2.03M-0.7% | $2.04M— | ||
| $6.48M+3.2% | $6.28M-3.4% | $6.5M-3.2% | $6.72M-3.0% | $6.93M-3.1% | ||
| —— | —— | —— | —— | —— | ||
| $61.54M+4.1% | $59.14M+21.3% | $48.76M+70.5% | $28.59M+1,399% | $1.91M+136% | ||
| $6.48M+3.2% | $6.28M-3.4% | $6.5M-3.2% | $6.72M-3.0% | $6.93M-3.1% | ||
| $2.02M-1.4% | $2.04M0.0% | $2.05M+0.9% | $2.03M-0.7% | $2.04M— | ||
| $72.22M+15.0% | $62.82M+9.3% | $57.5M-53.2% | $122.74M-14.8% | $144.1M+9.9% | ||
| $6.48M+3.2% | $6.28M-3.4% | $6.5M-3.2% | $6.72M-3.0% | $6.93M-3.1% | ||
| $2.02M-1.4% | $2.04M0.0% | $2.05M+0.9% | $2.03M-0.7% | $2.04M— | ||
| $148.85M+38.5% | $107.51M-4.3% | $112.34M-16.2% | $134.02M+0.1% | $133.93M+130% | ||
| $17.19M-19.0% | $21.23M-19.6% | $26.4M+10.4% | $23.91M+40.0% | $17.08M+49.6% | ||
| $596K-71.9% | $2.12M+6.6% | $1.99M-11.7% | $2.26M-23.4% | $2.95M-36.3% | ||
| $6.86M-22.1% | $8.81M+5.5% | $8.35M+401% | $1.67M-74.7% | $6.6M-45.4% | ||
| $753.56M+197% | $253.71M0.0% | $253.72M0.0% | $253.72M0.0% | $253.71M0.0% | ||
| $160K+0.6% | $159K0.0% | $159K0.0% | $159K0.0% | $159K+1.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are TG Therapeutics's total assets?
- TG Therapeutics (TGTX) holds $1.5B in total assets, up 132.8% year over year.
- How much debt does TG Therapeutics have?
- TG Therapeutics carries $753.6M in total debt against $583.1M of shareholders' equity, a debt-to-equity ratio of 1.29.
- How much cash does TG Therapeutics have?
- TG Therapeutics holds $442.2M in cash and equivalents.
- Can TG Therapeutics cover its short-term obligations?
- Its current ratio is 5.81 — current assets exceed current liabilities.
- Where does TG Therapeutics's balance sheet data come from?
- Every line is extracted from TG Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
